Literature DB >> 18977268

Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Nnaemeka C Iriemenam1, Atif H Khirelsied, Amre Nasr, Gehad ElGhazali, Haider A Giha, Thoraya M Elhassan A-Elgadir, Ahmed A Agab-Aldour, Scott M Montgomery, Robin F Anders, Michael Theisen, Marita Troye-Blomberg, Mustafa I Elbashir, Klavs Berzins.   

Abstract

Despite many intervention programmes aimed at curtailing the scourge, malaria remains a formidable problem of human health. Immunity to asexual blood-stage of Plasmodium falciparum malaria is thought to be associated with protective antibodies of certain immunoglobulin classes and subclasses. We have analysed immunoglobulin G profiles to six leading blood-stage antigens in relation to clinical malaria outcome in a hospital-based study in Sudan. Our results revealed a linear association with anti-AMA-1-IgG1 antibodies in children <5 years and reduced risk of severe malaria, while the responses of the IgG3 antibodies against MSP-2, MSP-3, GLURP in individuals above 5 years were bi-modal. A dominance of IgG3 antibodies in >5 years was also observed. In the final combined model, the highest levels of IgG1 antibodies to AMA-1, GLURP-R0, and the highest levels of IgG3 antibodies to 3D7 MSP-2 were independently associated with protection from clinical malaria. The study provides further support for the potential importance of the studied merozoite vaccine candidate antigens as targets for parasite neutralizing antibody responses of the IgG1 and IgG3 subclasses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977268     DOI: 10.1016/j.vaccine.2008.10.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

Review 1.  Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Authors:  Ruth D Ellis; Issaka Sagara; Ogobara Doumbo; Yimin Wu
Journal:  Hum Vaccin       Date:  2010-08

2.  A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray.

Authors:  Peter D Crompton; Matthew A Kayala; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Greta E Weiss; Douglas M Molina; Chad R Burk; Michael Waisberg; Algis Jasinskas; Xiaolin Tan; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; David L Narum; Xiaowu Liang; Ogobara K Doumbo; Louis H Miller; Denise L Doolan; Pierre Baldi; Philip L Felgner; Susan K Pierce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.

Authors:  Leoneide Érica Maduro Bouillet; Mariana Oliveira Dias; Natália Alves Dorigo; Andrew Douglas Moura; Bruce Russell; Francois Nosten; Laurent Renia; Erika Martins Braga; Ricardo Tostes Gazzinelli; Maurício M Rodrigues; Irene S Soares; Oscar Bruna-Romero
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

Review 4.  Vaccines against malaria.

Authors:  Amed Ouattara; Matthew B Laurens
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

5.  Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe Plasmodium falciparum malaria.

Authors:  Hodan Ahmed Ismail; Ulf Ribacke; Linda Reiling; Johan Normark; Tom Egwang; Fred Kironde; James G Beeson; Mats Wahlgren; Kristina E M Persson
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

6.  Chemokine levels and parasite- and allergen-specific antibody responses in children and adults with severe or uncomplicated Plasmodium falciparum malaria.

Authors:  B Wangala; A Vovor; R G Gantin; Y F Agbeko; C J Lechner; X Huang; P T Soboslay; C Köhler
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

7.  Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections.

Authors:  Cathrine Holm Olesen; Karima Brahimi; Brian Vandahl; Susana Lousada-Dietrich; Prajakta S Jogdand; Lasse S Vestergaard; Daniel Dodoo; Peter Højrup; Michael Christiansen; Severin Olesen Larsen; Subhash Singh; Michael Theisen
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

8.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

9.  Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.

Authors:  Ruth D Ellis; Laura B Martin; Donna Shaffer; Carole A Long; Kazutoyo Miura; Michael P Fay; David L Narum; Daming Zhu; Gregory E D Mullen; Siddhartha Mahanty; Louis H Miller; Anna P Durbin
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

10.  Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort.

Authors:  N O Duah; D J C Miles; H C Whittle; D J Conway
Journal:  Parasite Immunol       Date:  2010-02       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.